Strasbourg Cedex 2

• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended recruitment
  2023-507906-15-00 5 2019-01-30 Relapsing multiple sclerosis (RMS)
• STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Ended recruitment
  2024-516628-32-00 5 2019-01-24 Multiple Sclerosis
• The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended recruitment
  2024-510605-28-00 5 2018-11-27 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
• Study to evaluate the efficacy and safety of Durvalumab(MEDI4736) in combination with intravesical BCG for the treatment of patients diagnos … Ended recruitment
  2023-505341-23-00 5 2018-07-27 Non-muscle invasive bladder cancer
• International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended recruitment
  2024-513070-21-00 4 2018-02-15 Relapsed Acute Lymphoblastic Leukemia (ALL)
• A Phase 3 study to test the AG-120 in combination with Azacitidine in comparison with the use of Azacitidine alone in patients ≥ 18 Years of … Ended recruitment
  2024-514309-73-00 5 2018-02-06 Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
• Myechild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Fin … Ended recruitment
  2024-516112-21-00 5 2017-11-20 Newly diagnosed acute myeloid leukaemia (AML), high risk myelodysplast
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended recruitment
  2023-510298-33-00 4 2016-11-29 Prostate Cancer
• A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL … Ended recruitment
  2024-515846-18-00 7 2016-09-19 Newly diagnosed Diffuse Large B Cell Lymphoma
• CheckMate 274 Ended recruitment
  2022-500630-29-00 5 2016-05-06 Subjects with High Risk Invasive Urothelial Carcinoma
• RB SFCE 2009 : Adjuvant treatment in extensive unilateral retinoblastoma primary enucleated Ended recruitment
  2024-514844-10-00 4 2010-03-18 Retinoblastoma
• Treatment protocol for osteosarcomas in children, adolescents and adults including a randomized trial and biological studies Ended recruitment
  2024-514756-32-00 5 2007-03-19 High grade osteosarcoma
• A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1) Halted
  2023-503823-24-01 3 2024-04-15 Systemic Sclerosis
• MIVAR - Milrinone Infusion for VAsospam treatment in subarachnoid hemoRrhage Ended
  2024-515994-83-00 5 2026-01-13 aneurysmal subarachnoid hemorrhage with a vasospasm
• The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune D … Ended
  2024-518797-13-00 3 2025-07-10 systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic in
• Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP Ended
  2024-515386-34-00 4 2025-05-29 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Phase 1/2 Study of Cobolimab plus Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors Ended
  2024-511350-41-00 9 2025-03-13 Relapsed/Refractory Tumors
• A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended
  2023-507680-19-00 4 2024-11-28 Sjögren’s Syndrome
• PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease Ended
  2024-513647-86-00 4 2024-09-09 Patients displaying a non-classified, severe and resistant inflammator
• An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB) Ended
  2024-511446-39-00 4 2024-08-02 Dementia with Lewy Bodies (DLB)
• Optimization of the management of drepanocytosis patients treated with hydroxyurea: Interest of the pharmacological therapeutic follow-up Ended
  2024-515562-14-00 6 2024-07-19 Drepanocytosis
• A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Ended
  2022-502481-24-00 4 2024-05-23 Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

Showing 289–312 of 355 trials